PHASE I STUDY OF ADOPTIVE CELLULAR THERAPY OF SOLID TUMOR MALIGNANCIES

实体瘤恶性肿瘤过继细胞疗法的 I 期研究

• 批准号: 6114879
• 负责人: HARRY D BEAR
• 金额: $ 3.45万
• 依托单位: VIRGINIA COMMONWEALTH UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6114879
• 关键词: antineoplastic antibiotics; antineoplastics; bryostatin; clinical research; clinical trial phase I; cytotoxicity; drug administration rate /duration; drug adverse effect; drug screening /evaluation; human subject; interleukin 2; lymph nodes; neoplasm /cancer chemotherapy; neoplastic cell; outcomes research

To assess the feasibility, safety and toxicity of adoptive cellular therapy using three dose levels of tumorsensitized lymph node cells activated with Bryostatin, Lonomycin, and Interleukin-2 and expanded in low dose Interleukin 2.

评估收养细胞的可行性，安全性和毒性 使用三个剂量水平的肿瘤淋巴结细胞的治疗 用Bryostatin，Lonomycin和interleukin-2激活并扩展 低剂量白介素2。